Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang,
Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si
Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914
Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment
is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications.
We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring
c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall
survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate
(DCR). The median OS and PFS of all patients were More >
Login
Register
